BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma

Prior treatment

• pleural or peritoneal effusion that needs to be handled by surgical treatment;
• wound dystrophy, poor soft-tissue around implantation risky of non-healing given angiogenesis inhibitor at baseline;
• previously treated with VEGFR TKIs for more than 8 weeks
• previous treated with VEGFR TKIs but off treatment due to oncological assessment or dose-limiting complications given adequate interventions.

Other illness

• have had other kinds of malignant tumors at the same time;
• cardiac insufficiency or arrhythmia;
• uncontrolled complications, such as diabetes mellitus and so on;
• coagulation disorders or Hemorrhagic diseases ;
• combined with other infections or wound complications;

• age between 8 and 65 years;
• diagnosis of histologically confirmed advanced bone and soft tissue sarcoma excluding adipocytic tumor;
• identification of pulmonary lesion is mandatory;
• refractory to prior treatment consisted of standard National Comprehensive Cancer Network (NCCN) guideline recommended first-line chemotherapy;
• Eastern Cooperative Oncology Group(ECOG) performance status 0-2 with a life expectancy \>3 months;
• adequate renal, hepatic, and hemopoietic function;normal or controlled blood pressure;
• advanced stage that complete surgical resection of all lesions are infeasible;
• no serious thoracic comorbidities with adequate pulmonary function for daily living;
• previously treated with tyrosine kinase inhibitors (TKIs) for less than 8 weeks but off treatment due to manageable complications such as wound complications or pneumothorax without adequate interventions. The complications is resolved and disappeared at enrollment.